The SYNERGY biodegradable polymer everolimus eluting coronary stent: Porcine vascular compatibility and polymer safety study.

Autor: Wilson GJ; Department of Pediatric Laboratory Medicine, Division of Pathology and Research Institute, Division of Physiology and Experimental Medicine, Hospital for Sick Children, Toronto, Ontario, Canada and Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada., Marks A; Boston Scientific Corporation, Marlborough, Massachusetts., Berg KJ; Boston Scientific Corporation, Marlborough, Massachusetts., Eppihimer M; Boston Scientific Corporation, Marlborough, Massachusetts., Sushkova N; Boston Scientific Corporation, Marlborough, Massachusetts., Hawley SP; Department of Pediatric Laboratory Medicine, Division of Pathology and Research Institute, Division of Physiology and Experimental Medicine, Hospital for Sick Children, Toronto, Ontario, Canada and Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada., Robertson KA; Boston Scientific Corporation, Marlborough, Massachusetts., Knapp D; Boston Scientific Corporation, Marlborough, Massachusetts., Pennington DE; Boston Scientific Corporation, Marlborough, Massachusetts., Chen YL; Boston Scientific Corporation, Marlborough, Massachusetts., Foss A; Boston Scientific Corporation, Marlborough, Massachusetts., Huibregtse B; Boston Scientific Corporation, Marlborough, Massachusetts., Dawkins KD; Boston Scientific Corporation, Marlborough, Massachusetts.
Jazyk: angličtina
Zdroj: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions [Catheter Cardiovasc Interv] 2015 Nov 15; Vol. 86 (6), pp. E247-57. Date of Electronic Publication: 2015 May 23.
DOI: 10.1002/ccd.25993
Abstrakt: Aims: SYNERGY is a novel platinum chromium alloy stent that delivers abluminal everolimus from an ultrathin poly-lactide-co-glycide (PLGA) biodegradable polymer. This study evaluated the in vivo degradation of the polymer coating, everolimus release time course, and vascular compatibility of the SYNERGY stent.
Methods and Results: SYNERGY stents were implanted in arteries of domestic swine. Devices were explanted at predetermined time points (up to 120 days) and the extent of PLGA coating or everolimus remaining on the stents was quantified. Everolimus levels in the arterial tissue were also evaluated. A pathological analysis on coronary arteries of single and overlapping stents was performed at time points between 5 and 270 days. PLGA bioabsorption began immediately after implantation, and drug release was essentially complete by 90 days; PLGA absorption was substantially complete by 120 days (>90% of polymer was absorbed) leaving a bare metal SYNERGY stent. Vascular response was similar among SYNERGY and control stents (bare metal, polymer-only, and 3× polymer-only). Mild increases in para-strut fibrin were seen for SYNERGY at an early time point with no significant differences in all other morphological and morphometric parameters through 270 days or endothelial function (eNOS immunostaining) at 90 or 180 days. Inflammation was predominantly minimal to mild for all device types.
Conclusion: In a swine model, everolimus was released by 90 days and PLGA bioabsorption was complete shortly thereafter. The SYNERGY stent and its biodegradable polymer, even at a 3× safety margin, demonstrated vascular compatibility similar to bare metal stent controls.
(© 2015 Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz: